Rapport Therapeutics, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Dec 2022 | — | $-10.1M | — |
| Mar 2023 | — | $-4.0M | — |
| Jun 2023 | — | $-9.4M | $79.5M |
| Sep 2023 | — | $-13.1M | $159.4M |
| Dec 2023 | — | $-25.6M | $70.2M |
| Mar 2024 | — | $-39.6M | $74.3M |
| Jun 2024 | — | $336.9M | $110.2M |
| Sep 2024 | — | $323.1M | $39.3M |
| Dec 2024 | — | $305.4M | $56.8M |
| Mar 2025 | — | $285.8M | $57.6M |
| Jun 2025 | — | $263.5M | $55.1M |
| Sep 2025 | — | $511.6M | $251.4M |
| Dec 2025 | — | $484.7M | $52.6M |
| Mar 2026 | — | $471.5M | $78.1M |
| Jun 2026 | — | $422.9M | $63.6M |